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EMERGENCY CORONARY BYPASS GRAFTING FOR FAILED PERCUTANEOUS CORONARY
ARTERY STENTING: INCREASED COSTS AND PLATELET TRANSFUSION REQUIREMENTS
AFTER THE USE OF ABCIXIMAB
John M. Alvarez, FRACS, Melbourne, Australia
The adjunctive use of abciximab (ReoPro), a platelet
glycoprotein IIb/IIIa receptor antagonist, with aspirin as
pretreatment for percutaneous coronary artery stenting
(PTCS) has risen dramatically.1, 2 Reports on the out-
comes of patients who require emergency coronary bypass
grafting (CABG) for unsuccessful PTCS are scarce.3 This
report documents three cases. Table I outlines cardiopul-
monary bypass (CPB), hematologic, and coagulation as-
says. All patients had received aspirin (300 mg) and
abciximab (0.25 mg/kg/5 min bolus and 9 mg/500 ml
normal saline solution at 10 mg/min intravenous infusion)
before the operation. All had a profound bleeding diathe-
sis evident from skin incision and persisting for 4 to 5
hours after the operation.
Patients
PATIENT 1. A 38-year-old man had acute stent thrombo-
sis 14 days after PTCS to the left anterior descending
coronary artery. Cardiogenic shock ensued, necessitating
emergency CABG. Ticlopidine (Ticlid) at 250 mg twice a
day had been continued since the original PTCS.
CABG with a left internal thoracic artery graft to the
left anterior descending coronary artery and a saphenous
vein graft to a first diagonal was performed. After reversal
of heparinization, 5 units of platelets were given and the
chest was closed. By 60 minutes, the mediastinal blood
loss was 1500 ml. At resternotomy, no specific surgical
source was evident. A 1.5 mg dose of 1-deamino-8-D-
arginine vasopressin (Minirim) and a 4 3 106 kallikrein
activation unit (KIU) dose of aprotinin (Trasylol) were
given intravenously. An additional 1900 ml blood loss
occurred during the next 24 hours. The patient was
discharged on postoperative day 10.
PATIENT 2. A 73-year-old man in cardiogenic shock with
intraaortic balloon pump support was referred for opera-
tion with a postinfarct inferior ventricular septal rupture;
PTCS to the proximal right coronary artery had been
performed. The operation entailed polyethylene tereph-
thalate (Dacron) patch closure of the ventricular septal
defect and placement of four venous coronary bypass
grafts. Because of the previous experience, intravenous
aprotinin (“high” Hammersmith dose [7 3 106 KIU]) was
given at induction, and after CPB 10 units of platelets
were given. This patient died of low cardiac output
syndrome 96 hours after the operation.
PATIENT 3. A 39-year-old woman, in cardiogenic shock
from an evolving anterolateral acute myocardial infarction
after PTCS to the circumflex coronary artery required
emergency CABG. A left internal thoracic artery graft to
the left anterior descending coronary artery and two
additional venous bypass grafts were performed. “High”
Hammersmith dose aprotinin was used (total 5 3 106
KIU); after CPB, 10 units of platelets were also given. The
patient was discharged home 6 days after the operation.
Discussion. This limited experience focuses attention
on the potential impact of abciximab on patients under-
going emergency CABG; the message is sharp. In all three
cases, results of history, physical examination, and hema-
tologic and coagulation assays were normal before the
operation, yet perioperative blood loss was in excess of
what was expected. Aprotinin in the “high” Hammersmith
dose and immediate, repeated platelet transfusions after
CPB appear necessary and effective in reducing mediasti-
nal blood loss.
Abciximab use is based on the reduction in the 30-day
primary end point (death, acute myocardial infarction,
revascularization) reported by the EPIC1 (placebo 12.8%
vs treated 8.5%), EPILOG2 (placebo 11.7% vs treated
5.2%), and CAPTURE (placebo 15.9% vs treated 11.3%)
trials.1, 2 Only the EPIC trial reported on patients requir-
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Table I. Hematologic, coagulation, and
cardiopulmonary data before and after bypass
Case 1 Case 2 Case 3
Before After Before After Before After
Hb (gm/dl) 14.3 10.3 13.6 9.6 12.9 9.5
Plat (106 cells/ml) 302 251 367 301 396 296
INR 1.1 1.2 1.0 1.1 1.0 1.1
APTT (sec) 31 35 30 33 29 31
Fib (m/dl) 3.7 2.1 4.1 2.0 3.6 2.4
ACT (sec) 135 105 146 110 141 108
CPB (min) 51 174 56
ACC (min) 21 120 27
Blood loss* (ml) 3400 790 720
Transfusions (units)
Platelets 45 16 23
FFP 20 5 0
Packed cells 6 4 4
Hb, Hemoglobin; Plat; platelet count; INR, International Normalized Ratio;
APTT; kaolin-based partial thromboplastin time (normal 35 to 55 sec); Fib;
fibrinogen, ACT; activated clotting time (normal 105 to 120 sec); ACC,
Aortic crossclamp time; FFP, fresh-frozen plasma.
*24-hour mediastinal loss.
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ing urgent CABG for failed PTCS.3 Their operative
mortality rate of treated versus placebo groups is disturb-
ing (placebo 8% versus treated 29.4% for bolus plus
infusion). Claims by the EPIC investigators that these
results are acceptable are contradicted by their quoted
references. Eight references had operative mortality rates
ranging from 0% to 6.3%. In the remaining two, the Mid
America Heart group had a total series operative mortal-
ity rate of 6.3% (18/286).4 Of the 113 emergency CABGs,
45% were performed on patients in cardiogenic shock
(mortality rate 15%) or receiving cardiopulmonary resus-
citation (mortality rate 62%). The remainder of patients
undergoing emergency CABG had a mortality rate of 3%
to 4%. The Mid America Heart group quote the mortality
rate for the 1983 National Heart and Lung Institute
percutaneous transluminal coronary angioplasty surgical
registry as 6.9%. In the series of Buffet and coworkers,5 all
were emergency cases; 23% of patients were in cardio-
genic shock or requiring cardiopulmonary resuscitation.
Excluding these cases in extremis, accounting for 14 of 19
deaths, the operative mortality rate for the remainder of
emergency cases was 6.5%.
Thus, the 29.4% operative mortality rate of the EPIC
trial is not reflective of the published mortality rates of 3%
to 6% for the same group of patients undergoing CABG,
particularly because the EPIC patients are not compara-
ble with the in extremis cases reported on by Buffet and
coworkers5 and the Mid America Heart Institute.4 This
30-day, nominal 4% to 6% benefit attributed to abciximab
for PTCS must be questioned if surgical mortality rate is
increased among those needing CABG for failed PTCS.
In addition, blood transfusion costs were $23,500 Aus-
tralian, the cost of abciximab was $1500 Australian/case,
and three patients were exposed to 131 donors. In Aus-
tralian public hospitals, $28,000 Australian would cover
70% of the cost of all three CABGs. Trials analyzing the
effects of this drug must include data on patients who
required urgent CABG if sensible conclusions are to be
reached. Before giving abciximab, the cardiologist must
therefore critically assess the risk of PTCS failure, because
the impact of abciximab on CABG is not benign.
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TRANSIENT REDUCTION WITHOUT NORMALIZATION OF BRAIN NATRIURETIC PEPTIDE EARLY
AFTER HEART TRANSPLANTATION
Bernard Geny, MD, PhD, Marguerite Follenius, PhD, Eric Epailly, MD, Arnaud Charpentier, MD,
Gabrielle Brandenberger, PhD, Bernard Eisenmann, MD, Pascal Haberey, MD, and Franc¸ois Piquard, PhD,
Strasbourg, France
Brain natriuretic peptide (BNP), a recently discovered
cardiac hormone, is secreted mainly by the cardiac ventri-
cles and has potent diuretic, natriuretic, and vasorelaxant
properties. Circulating BNP levels are increased in pa-
tients with heart failure in proportion to the severity of the
disease and may have important compensatory renal,
cardiovascular, and endocrinologic actions. Cardiac trans-
plantation, a recognized treatment for end-stage heart
failure, normalizes the neuroendocrine balance, but atrial
natriuretic peptide and BNP levels remain elevated in
heart-transplant recipients.1 Contrasting with the numer-
ous studies focused on atrial natriuretic peptide in heart
transplantation2 and despite the greater potential benefi-
cial effects of BNP, few data are available concerning the
BNP level response to cardiac transplantation.3, 4
Method and results. Plasma BNP levels were deter-
mined by radioimmunoassay with kits from Peninsula
Laboratories (Belmont, Calif.) after extraction by Sep Pak
C18 cartridges (Waters Chromatography, Milford, Mass.)
in 25 patients just before and daily during the first week
after either heart transplantation (n 5 15) or coronary
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